Novartis AG stated that by 2029, the company's revenue will grow at a rate of 6% per year, higher than the previous expectation of 5%. Novartis has raised the peak sales expectations for its drugs Cosentyx, Kisqali, Kesimpta, Pluvicto, and Leqvio, most of which are expected to gain exclusive operation rights in the USA in the 2030s or later.
基于癌症和炎症药物乐观前景 诺华制药上调中期销售预期
Novartis AG raises mid-term sales expectations based on optimistic outlook for cancer and anti-inflammatory drugs.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated